- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Drug Evaluation and Research
This guidance describes how a prospective abbreviated new drug application (ANDA) applicant 19 may request a letter stating that FDA has determined: (1) that the prospective applicant’s 20 bioequivalence (BE) study protocol contains safety protections comparable to those in the risk 21 evaluation and mitigation strategy (REMS) with elements to assure safe use (ETASU) applicable 22 to the reference listed drug (RLD), and (2) that FDA will not consider it a violation of the REMS 23 for the RLD sponsor to provide a sufficient quantity of the RLD to the interested generic firm or 24 its agent to allow the firm to perform the testing necessary to support its ANDA.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2014-D-1891.